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A NOVEL ANTI-CD22 IMMUNOTOXIN, MOXETUMOMAB PASUDOTOX
(HA22, CAT-8015): ACTIVITY IN PEDIATRIC PATIENTS WITH RELAPSED
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AFTER ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (SCT)
Shah, N.N.1, Bhojwani, D.2, Silverman, L.B.3, Whitlock, J.A.4,
Richards, K.1, Stetler-Stevenson, M.5, Buzoianu, M.6, Ibrahim, R.6,
Pastan, I.7, Wayne, A.S.1,7 1National Institutes of Health, Bethesda,
MD; 2St. Jude Children’s Research Hospital, Memphis, TN; 3Dana-
Farber Cancer Institute/Children’s Hospital Boston, Boston, MA; 4Hospi-
tal for Sick Children, Toronto, ON, Canada; 5National Institutes of
Health, Bethesda, MD; 6MedImmune, LLC, Gaithersburg, MD; 7Na-
tional Institutes of Health, Bethesda, MD
Background: Despite the curative potential of SCT for pediatric
ALL, relapse remains the most frequent cause of treatment failure.
Management of relapse after SCT is complicated by drug resistance,
limited utility of DLI, treatment-related toxicities, and GVHD.
Moxetumomab pasudotox (MP) is a recombinant anti-CD22 immu-
notoxin with properties that warrant evaluation in the peritransplant
setting. Cytotoxicity is mediated by targeted inhibition of protein
synthesis in CD22+ cells, an antigen expressed on most B-lineage
ALL blasts, and no immune effector cells are required for activity.
Methods: A pediatric phase I trial of MP is being conducted for
CD22+ hematologic malignancies (ClinicalTrials.gov
NCT00659425). Doses are administered at 5-40 mg/kg IV QODx6
every 21 days. An initial cohort (A) included 1 patient each at the first
3 dose levels followed by standard 3+3 dose escalation starting at 30
mg/kg. In an attempt to prevent capillary leak syndrome (CLS), an
ongoing cohort (B) receives dexamethasone around MP doses.
Results: 23 patients have been treated to date. The most common
drug-related adverse events (AEs) were mild, reversible increased
weight, transaminase elevation, and hypoalbuminemia. Treatment
was discontinued in 1 patient after dose 1 due to ALL-related com-
plications. Dose-limiting CLS was observed in 2 patients in Cohort
A (30 mg/kg; grade 3 and 4, deemed drug-related serious AEs) and in
no patients in Cohort B. 1 patient treated at 40 mg/kg developed re-
fractory hypercalcemia, that was possibly drug-related, and died of
cardiac arrhythmia during central venous catheter placement. That
dose level (5B) was expanded and is accruing. 12 of 23 patients had
prior SCT for ALL. Time from SCT to relapse was 3-12 mos (me-
dian, 9) and from SCT to treatment withMP was 4-34 mos (median,
13). 9 of 12 patients who had previously undergone SCTwere evalu-
able for response. 3 (33%) patients had complete responses (CR) and
4 (44%) had hematological activity (.50% blast reduction and/or
improvement in neutrophil/platelet counts). 1 patient with a CR
confirmed by flow cytometry proceeded to 2nd SCT.
Conclusions:MP is active in relapsed pediatric ALL after SCT.No-
tably, 3 of 4 CRs observed so far on this trial have been in patients
treated for post-transplant relapse. The observed antileukemic activ-
ity and safety profile of MP, coupled with its unique properties, war-
rant further study in the peritransplant setting.
This study was sponsored by MedImmune, LLC.
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TREOSULFAN, FLUDARABINE AND ALEMTUZUMAB CONDITIONING FOR
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH
PRIMARY IMMUNODEFICIENCY: UK EXPERIENCE
Slatter, M.1, Rao, K.2, Chiesa, R.2, Amrolia, P.2, Nademi, Z.1, Flood, T.1,
Abinun, M.1, Cant, A.1, Hambleton, S.1, Goulden, N.2, Davies, G.2,
Qasim, W.2, Gaspar, H.B.2, Gennery, A.1, Veys, P.2 1Newcastle upon
Tyne Hospital NHS Foundation Trust, Newcastle upon Tyne, United
Kingdom; 2Great Ormond Street Hospital NHS Trust, London, United
Kingdom
Ninety-eight children received Treosulfan 42g/m2 or 36g/m2 (\1
year), Fludarabine 150mg/m2 with Alemtuzumab (in most), prior to
Hematopoietic Cell Transplantation (HCT) for Primary Immuno-
deficiency (PID) or Severe Immune Dysregulation between 2004
and July 2011.
Median age at transplant was 10 months (range: 1.4 to 191); 55%
patients were 12 months or younger. Donors were: unrelated (79), of
which 28 were cord blood (CB), matched sibling donors (3), other
matched family donors (13), haploidentical donors (3). Stem cellsource was: PBSC (39), BM (31), CB (28). Median follow up was
18.5 months (range: 2 to 82).
Overall survival was 85%. Of the 15 deaths, 8 patients had HLH
many of whom were not in remission at the time of HCT. There
was no VOD and no toxicity related deaths. Eighteen % had
GVHD, only 7% . grade II. One patient rejected their graft; 35
of 55 (64%) more than 1 year post transplantation had 100% donor
chimerism in all cell lineages. Increased use of PBSC favoured im-
proved donor myeloid chimerism and with the use of Alemtuzumab
the incidence of significant GVHDwas not increased. High levels of
donor chimerism are of particular importance in diseases such as
Wiskott Aldrich Syndrome and Chronic Granulomatous Disease.
Long-term follow up is required to determine the gonadotoxic ef-
fects of this approach in comparison to Busulfan containing regi-
mens, but the combination of Treosulfan, Fludarabine and
Alemtuzumab is an ideal choice of conditioning forHCT in PID, as-
sociated with good lymphoid and myeloid engraftment and low reg-
imen related toxicity.86
EARLY HEMATOPOIETIC STEM CELL TRANSPLANT IS ASSOCIATED WITH
IMPROVED OUTCOMES IN CHILDREN WITH MDS
Christiansen, E.C.1, Trotz, B.A.2, Cao, Q.3, Lipsitz, E.2, Weigel, B.J.2,
Stefanski, H.E.4, Verneris, M.R.4, Burke, M.J.2, Smith, A.R.4 1Univer-
sity of Minnesota, Minneapolis, MN; 2University of Minnesota, Minneap-
olis, MN; 3University of Minnesota, Minneapolis, MN; 4University of
Minnesota, Minneapolis, MN
Background:Childhoodmyelodysplastic syndrome (MDS) is a rare,
heterogeneous disorder that is clinically distinct from adult MDS.
Hematopoietic stem cell transplant (HSCT) is the treatment of
choice, but there is no consensus regarding patient, disease, or treat-
ment-related factors that predict outcomes after HSCT.
Materials andMethods:Weperformed a retrospective review of 37
consecutive pediatric patients who received allogeneic HSCT for
MDS at the University of Minnesota Amplatz Children’s Hospital
between 1990 and 2010.
Table. Patient Characteristics
Total (%)Total Patients 37
Gender
Male 18 (49%)
Female 19 (51%)
Median Age at Diagnosis 11 (range 1-21)
Year of HSCT
1990-1999 24 (65%)
2000-2010 13 (35%)
Time from Diagnosis to HSCT (days)
<140 18 (49%)
$140 19 (51%)
Type of MDS
Primary 20 (54%)
Secondary 17 (46%)
Blast Count Pre-HSCT
<5% 27 (73%)
$5% 10 (27%)
Cytogenetics*
Monosomy 7 21 (57%)
Trisomy 8 7 (19%)
Normal/Other 8 (22%)
MDS Classification
RC 30 (81%)
RAEB 7 (19%)
IPSS Risk
Low 1 (3%)
Int-1 15 (40%)
Int-2 21 (57%)
Pre-HSCT Chemotherapy(Continued )
Oral Presentations S235Table. (Continued )Total (%)Yes 6 (16%)
No 31 (84%)
Myeloablative Conditioning 37 (100%)
Graft Source
UCB 9 (24%)
MRD 15 (41%)
MURD 7 (19%)
MMURD 6 (16%)
HLA Match
Match 20 (54%)
Mismatch 17 (46%)
CSA containing GVHD Prophylaxis
Yes 29 (78%)
No 8 (22%)*Cytogenetics not available for 1 patient
Results: Neutrophil engraftment occurred in 89% of patients at
a median of 23 days (range 12-40). Patients transplanted after
year 1999 were more likely to engraft (RR 2.27, p 5 .04). Overall
survival (OS) was 70% and 53% at 1 and 3 years. In multivariate
analysis (MVA), OS was increased in patients who did not receive
pre HSCT chemotherapy (RR 0.04, p 5 .01) and decreased in
those with an IPSS score of Int-2 (RR 11.96, p 5 .03). Disease
free survival (DFS) was 62% and 48% at 1 and 3 years. In MVA,
factors associated with improved DFS at 3 years include having sec-
ondary MDS (RR 0.13, p 5 .02), undergoing HSCT after 1999 (p
5 .02 at 3 years), not receiving pre HSCT chemotherapy (RR 0.06,
p\.01), and a short interval (\140 days) from diagnosis to trans-
plant (RR 0.21, p 5 .03). Those with an IPSS score of Int-2 had
a significantly lower DFS (RR 3.96, p 5 .03). WHO classification,
cytogenetics and pre HSCT blast percentage had no significant im-
pact on either OS or DFS. The relapse rate at 2 years was 20%.
Factors associated with decreased relapse include having secondary
MDS (RR 0.04, p\.01) and not receiving pre HSCT chemotherapy
(RR 0.21, p 5 .03). Treatment-related mortality (TRM) was 25%
at 1 year. The risk of TRM was increased in patients with a pre
HSCT blast count $ 5% (RR 6.65, p 5 .01) and was decreased
in patients who did not receive pre HSCT chemotherapy (RR
0.07, P 5 .02). At 100 days the cumulative incidence of grades
II-IV and III-IV acute graft versus host disease (GVHD) was
40% and 16%, respectively. The incidence of chronic GVHD at
one year was 19%.
Conclusions: Our results suggest that in order to achieve optimal
outcomes, children with MDS should be referred for allogeneic
HSCT soon after diagnosis and that unlike in adult MDS, pre
HSCT chemotherapy does not appear to improve outcomes.87
OUTCOME OF POOR RESPONSE PAEDIATRIC AML USING EARLY SCT
Wareham, N.E.1, Heilmann, C.1, Abrahamsson, J.2, Forestier, E.3,
Gustafsson, B.4, Ha, S.-Y.5, Heldrup, J.6, Jahnukainen, K.7,
Jonsson, O.G.8, Lausen, B.1, Palle, J.9, Zeller, B.10, Hasle, H.11 1The
University Hospital Rigshospitalet, Copenhagen, Denmark; 2The Queen
Silvia Children’s Hospital, Gothenburg, Sweden; 3University of Umea,
Umea, Sweden; 4Karolinska Institute, Karolinska University Hospital,
Huddinge, Sweden; 5QueenMary Hospital, Hong Kong; 6University Hos-
pital Lund, Lund, Sweden; 7Hospital for Children and Adolescents, Uni-
versity of Helsinki, Helsinki, Finland; 8University Hospital, Reykjavık,
Iceland; 9University Children’s Hospital, Uppsala, Sweden; 10Oslo Uni-
versity Hospital Rikshospitalet, Oslo, Norway; 11Aarhus University Hospi-
tal Skejby, Aarhus, Denmark
Background:Children with poor response acute myeloid leukaemia
(AML) or refractory AML are generally considered to have a very
poor outcome. Allogeneic stem cell transplantation (SCT) has
been recommended for these children however, the advantage of
SCT as opposed to continuous chemotherapy is not clear. Theaim of this study was to investigate survival for poor response
AML patients treated with SCT.
Procedure: The patients were treated according to the NOPHO-
AML 2004 protocol and data were collected from the NOPHO-
AML database. All patients received AIET (Cytarabine, Idarubicin,
Etoposide, Thioguanine) and AM (Cytarabine, Mitoxantrone) as
induction therapy. Poor response was defined as more than 15%
blasts on day 15 after AIET and/or .5% blasts after AM. These
patients proceeded to allo-SCT if a donor (family or unrelated)
was available.
Results:Twenty-five of 230 patients had a poor response. SCT was
performed in 21, using unrelated donors in 16, matched sibling do-
nors (MSD) in 4 and a haploidentical donor in one of the transplants.
Themedian follow-up was 2.9 years (range 0.7-7.3) and 3-year prob-
ability of survival 89%. Of five patients with more than 5% blasts at
time of SCT four remain alive.
Conclusions: The poor responders had a significantly better prog-
nosis than has previously been reported for patients with high blast
count on day 15 and it seems that SCT is the treatment of choice
for children with poor response AML.STEM CELL BIOLOGY88
EGF SIGNALING REGULATES HEMATOPOIETIC REGENERATION FOL-
LOWING TOTAL BODY IRRADIATION
Doan, P.L.1, Russell, J.L.1, Himburg, H.A.1, Helms, K.1, Sullivan, J.M.2,
Jeffords, L.B.2, Chao, N.J.1,4, Kirsch, D.G.2,3, Chute, J.P.1,3 1Duke Uni-
versity Medical Center, Durham, NC; 2Duke University Medical Center,
Durham, NC; 3Duke University Medical Center, Durham, NC; 4Duke
University Medical Center, Durham, NC
VEGFR2+ sinusoidal endothelial cells are necessary for normal
hematopoietic reconstitution following myelosuppressive chemo-
or radiotherapy (Hooper et al, Cell Stem Cell 2009). However, the
mechanisms through which BM endothelial cells promote HSC re-
generation remain unknown.We developed a mouse model in which
mice bearing cell-specific deletion of Bak and Bax in Tie2+ cells
(Tie2Cre;Bak1-/-;BaxFl/- mice) were irradiated with sublethal and
lethal doses of total body irradiation to assess whether protection
of BM Tie2+ ECs from radiation-induced apoptosis could protect
the hematopoietic compartment from myeloablative toxicity.
Tie2Cre;Bak1-/-;BaxFL/- mice demonstrated protection of BM
HSCs and 100% survival following lethal dose TBI (750 cGy),
whereas mice that retained Bax expression in Tie2+ cells demon-
strated depletion of BM HSCs and only 10% survival (p\0.0001).
To determine the mechanism through which Tie2+ BM ECs regu-
late HSC regeneration, we performed a cytokine array screen of
BM serum from Tie2Cre;Bak1-/-;BaxFl/- mice and compared with
Tie2Cre;Bak1-/-;BaxFl/+ mice and C57Bl6 mice. Among several
genes which were up- or down-regulated in the BaxFl/- mice, we
found an 18-fold increase in the concentration of epidermal growth
factor (EGF) compared to BaxFl/+ and C57Bl6 mice (p5 0.04). We
then showed that BM ECs express EGFR and BM ckit+sca-1+lin-
cells also express EGF in C57Bl6 mice. Interestingly, antibody
blockade of EGF in vitro blocked the ability of BaxFl/- ECs to sup-
port HSC regeneration following 300 cGy irradiation. Furthermore,
systemic administration of EGF to irradiatedmice caused a profound
recovery of BMHSC and progenitor cells compared to saline treated
control mice. Similarly, administration of erlotinib, an EGFR antag-
onist, caused a significant delay in recovery of BMHSCs in mice fol-
lowing high dose irradiation. Mechanistic studies revealed that
treatment of HSCs with EGF significantly increased EGFR phos-
phorylation and downstream activation of Akt signaling. Further-
more, inhibition of Akt signaling blocked the beneficial effect of
EGF in mediating the recovery of HSCs following radiation expo-
sure, suggesting that EGF action on HSC regeneration was medi-
ated by Akt activation. These data demonstrate that EGF is an
important regulator of HSC regeneration in vivo and a potential
new target for therapies to accelerate hematopoietic reconstitution
following chemotherapy and radiation exposure.
